• 1
    Santen RJ. Clinical Review 37 Endocrine treatment of prostate cancer. J Clin Endocrinol Metab 1992; 75: 6859
  • 2
    Conn PM, Crowley WF Jr. Gonadotrophin-releasing hormone and its analogues. N Engl J Med 1991; 324: 93103
  • 3
    Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. Rev Urol 2005; 7 (Suppl. 5): S312
  • 4
    Waxman J, Man A, Hendry WF et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. BMJ 1985; 291: 13878
  • 5
    Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144: 147980
  • 6
    Boccon-Gibod L, Laudat MH, Dugue MA, Steg A. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by LHRH analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol 1986; 12: 4002
  • 7
    Heidenreich A, Aus G, Abbou CC et al. Guidelines on Prostate Cancer. Arnhem, the Netherlands: European Association of Urology, 2007
  • 8
    Moul JW, Chodak G. Combination hormonal therapy: a reassessment within advanced prostate cancer. Prostate Cancer Prostatic Dis 2004; 7 (Suppl. 1): S27
  • 9
    Zinner NR, Bidair M, Centeno A, Tomera K. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial. Urology 2004; 64: 117781
  • 10
    Huirne JAF, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001; 358: 1793803
  • 11
    PlenaxisTM (abarelix for injectable suspension) Product description. Available at: Accessed 21 August 2008
  • 12
    National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology – Prostate Cancer V.1. 2008
  • 13
    Van Poppel H, Tombal B, De La Rosette JM, Persson B-E, Jensen J-K, Kold Olesen T. Degarelix: a novel gonadotrophin-releasing hormone (GnRH) blocker – results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. Eur Urol 2008; 54: 80515
  • 14
    Gittelman M, Pommerville PJ, Persson BE, Jensen J-K, Olesen TK. A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 2008 (in press)
  • 15
    Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol 2006; 2: 67796
  • 16
    World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. (Amended by the 52nd WMA General Assembly, Edinburgh, Scotland.; notes of clarification issued in 2002 and 2004), October 2000
  • 17
    Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 ( August 9, 2006 Accessed 20 August 2008
  • 18
    Ben-Josef E, Yang SY, Ji TH et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999; 161: 9706
  • 19
    Porter AT, FACRO, Ben-Josef E. Humoral mechanisms in prostate cancer: a role for FSH. Urol Oncol 2001; 6: 1318
  • 20
    Tombal B, Berges R. How good do current LHRH agonists control testosterone? Can this be improved with Eligard®? Eur Urol Suppl 2005; 4: 306
  • 21
    Berges R, Bello U. Effect of a new leuprorelin formulation on testosterone levels in patients with advanced prostate cancer. Curr Med Res Opin 2006; 22: 64955
  • 22
    Morote J, Orsola A, Planas J et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007; 178: 12905
  • 23
    Sharifi R, Browneller R. Leuprolide Study Group. Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer. J Urol 2002; 168: 10014
  • 24
    Samson DJ, Seidenfeld J, Schmitt B et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002; 95: 36176
  • 25
    Ako D, Shiba M, Arai Y et al. Skin reactions to 3-month depot type of luteinizing hormone-releasing hormone agonist therapy. JMAJ 2006; 49: 4854
  • 26
    Eligard (7.5 mg). US product label November 2007